U.S. markets closed

Graybug Vision, Inc. (GRAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.6506-0.0194 (-2.90%)
At close: 12:18PM EST
0.6700 +0.02 (+2.98%)
After hours: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Bollinger Bands

Bollinger Bands

Previous Close0.6700
Bid0.6505 x 3200
Ask0.7000 x 1100
Day's Range0.6506 - 0.7000
52 Week Range0.6300 - 2.7400
Avg. Volume67,590
Market Cap14.029M
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-1.6220
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GRAY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Graybug Vision, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/26/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • Benzinga

    Graybug Vision Agrees To Merge With Inflammatory Disease-Focused Biopharma

    Graybug Vision Inc (NASDAQ: GRAY) and CalciMedica Inc (CalciMedica) have announced a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will further develop CalciMedica's lead product candidate Auxora for inflammatory diseases, such as acute pancreatitis, asparaginase-associated pancreatitis, acute kidney injury, and acute hypoxemic respiratory failure. Auxora, which modulates the immune response and protects against tissue cell injury, has bee

  • GlobeNewswire

    Graybug and CalciMedica Enter into Definitive Merger Agreement

    – Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joi

  • GlobeNewswire

    Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

    REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the s